JTJarell Jie-Rae Tan

Jarell Jie-Rae Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jarell Jie-Rae Tan has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Magnitude of portal pressure reduction and clinical outcomes in randomized trials

    by Matthew Tam, Irene Pascual, Jarell Jie-Rae Tan, Daniel Veldhuijzen van Zanten, Beverley Kok, Shuen Sung, Janice Y. Kung, Yu Jun Wong, Juan G. Abraldes

  • Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease

    by Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong

    Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized in patients with primary biliary cholangitis (PBC). While metabolic comorbidities are expected to worsen outcomes, the clinical impact of MASLD in PBC remains uncertain. We investigated whether concomitant MASLD modifies hepatic and cardiovascular outcomes in patients with PBC. Methods: We conducted a retrospective international cohort study using de‐identified electronic health records from the TriNetX global research network, including 172 healthcare organizations between 2010 and 2025. Adult patients with PBC with and without MASLD were matched using propensity score matching (1:1) to balance baseline characteristics. The primary outcomes were all‐cause mortality. Major adverse cardiovascular events (MACE) and hepatic decompensation were evaluated as secondary outcomes. Additional outcomes included hepatocellular carcinoma, liver transplantation, and one‐year biochemical response (ALP normalization). Results: Among 30 934 patients with PBC (78.9% female; mean age 68 years), 5955 (19.2%) had concomitant MASLD. After matching, 10 856 patients (5428 per group) were included. Over a mean follow‐up of 4 years, patients with PBC‐MASLD had a lower risk of all‐cause mortality (HR 0.60; 95% CI 0.54–0.67) and hepatic decompensation (HR 0.82; 95% CI 0.71–0.93), but higher risk of MACE (hazard ratio [HR] 1.30; 95% CI 1.14–1.48). One‐year biochemical response rates were comparable between groups. Findings remained consistent across multiple sensitivity analyses. Conclusion: MASLD identifies a distinct metabolic phenotype of PBC characterized by increased cardiovascular risk but paradoxically lower mortality and hepatic decompensation. These findings highlight the need to integrate cardiovascular risk assessment into the management of patients with PBC.


  • Open Access

    Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis

    by Ambrose Hon-Lam Chung, Jarell Jie-Rae Tan, Roe Xin Jacqueline Yap, Jing Hong Loo, Wei Xuan Tay, Corrine Lee Singh, Shi Jie Ong, Aidan Yuan Jie Low, Yikun Lin, Ellina Lytvyak, et al.

    Background: Patients with primary biliary cholangitis (PBC) often suffer from debilitating symptoms, yet the overall symptom burden has not been systematically quantified. This study aims to systematically review the prevalence and severity of the symptom burden in PBC patients. Methods: We conducted a systematic search of 3 electronic databases to include studies that reported the prevalence and severity of PBC symptoms. Subgroup analyses were performed based on study type, publication year, risk of bias, study location, sex, and latitude. Results: A total of 25 studies involving 13,178 patients were included. Fatigue was the most common symptom, affecting 51% of patients, followed by pruritus at 33%. Severe fatigue and severe pruritus were reported in 23% and 10% of patients, respectively. The prevalence of fatigue was significantly higher in more recent studies, those with smaller sample sizes, and studies published as abstracts. Fatigue score was significantly higher in female patients compared with males. Severe fatigue was more prevalent in studies conducted in North America/Europe than those from Asia (26% vs. 8%, p =0.0005), and in studies with a higher proportion of patients with cirrhosis (28% vs. 8%, p =0.0005). Despite the high burden, only 36% of PBC patients with pruritus received anti-pruritic treatment, with antihistamines being the most frequently prescribed medication. Conclusions: Over half of PBC patients experience significant symptom burden, with substantial ethnic disparities identified. The proportion and quality of appropriate symptom management in PBC are suboptimal. There remains an unmet need for standardized assessment, consistent reporting, and improved management strategies for PBC-related symptoms in future research.

  • Open Access

    Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis

    by Jarell Jie-Rae Tan, Ellina Lytvyak, Joo Wei Ethan Quek, Corrine Lee Singh, Yuan Jie Aidan Low, Shi Jie Ong, Mark Muthiah, Yu Jun Wong, Aldo J. Montano-Loza

    Background: The clinical impact of hepatic steatosis (HS) among patients with autoimmune liver disease (AILD) remains unclear. We aim to determine the prevalence of HS and its clinical impact on treatment response and outcomes in patients with AILD. Methods: We systematically searched 3 electronic databases until 17 December 2025, including all studies that reported the prevalence, clinical impact, and treatment response of AILD patients with concomitant HS. The temporal trend of HS prevalence was analyzed using a quasi-Poisson regression model, with annual percent changes (APC, %) calculated. Results: Overall, 44 studies, comprising 19,898 patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) were included. The pooled prevalence of HS in patients with AIH, PBC, and PSC was 27.3%, 32.9%, and 21.6%, respectively. HS prevalence has significantly increased among PBC patients since 2010 (APC: +37.4%). While concomitant HS was associated with a higher risk of hepatic decompensation (OR: 1.6, 95% CI: 1.3–2.1, I 2 =0%) and hepatocellular carcinoma (OR: 1.8, 95% CI: 1.3–2.6, I 2 =0%) in patients with AIH, HS did not influence the clinical outcomes in patients with PBC. Treatment response in AIH and PBC was not influenced by concomitant HS. Available data on PSC with concomitant HS were insufficient to assess its association with clinical outcomes. Conclusions: AIH patients with concomitant HS had worse outcomes than those without HS; whereas HS did not influence the clinical outcomes in patients with PBC. Future research evaluating the impact of HS on PSC and overlap syndrome is much needed.


  • Open Access

    Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis

    by Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong